Equity
€48,974 ▲ 17.2%
FJ Pharma paid out €833 in dividends. That is 10% of the 2025 profit.
FJ Pharma
Lifetime
4 annual accounts with figures on one time axispeak of €31,061 in 2023
€13,684▼ 13.8%
peak of €16,457 in 2022
€8,035▼ 18.1%
peak of €48,974 in 2025
€48,974▲ 17.2%
€17,429▼ 22.0%
Board1 name since 2021
1 director
Documentsfilings and deeds
02-03-2026151 days before the deadline
2025micro format
Gross margin from €15,871 to €13,684Registered office moved from Hoeselt to Bilzen-Hoeselt 07-04Dividend €833Equity from €41,772 to €48,974Debts from €22,336 to €17,429
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,973 companies had the same profile as FJ Pharma has now. Each dot stands for 68 companies, two years later.
94.9%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,973 companies, not a prediction for FJ Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0771593428
Registered office moved from Hoeselt to Bilzen-Hoeselt
The registered office moved from O.-L.-Vrouwstraat 2, 3730 Hoeselt to Boeleberg 2, 3730 Bilzen-Hoeselt · General meeting of 01-03-2025 · Gazette deed
Incorporation
Appointment: (director) · Registered office clause: Onze-Lieve-Vrouwstraat 2, 3730 Hoeselt · published on 23-07-2021 · Gazette deed
First establishment
At the time the registered office was still in Hoeselt, O.-L.-Vrouwstraat 2.
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| FJ Pharma Bilzen-Hoeselt | €66,403 | €13,684 | 73.8% | - |
| NR INVESTMENTS Hasselt | €64,115 | €12,357 | 87.4% | - |
| FIACOM Diepenbeek | €64,330 | €12,767 | 52.4% | - |
| H21 Hasselt | €71,526 | €15,336 | 2.8% | - |
| GLAD Tessenderlo-Ham | €76,638 | €13,562 | 81.0% | - |
| HR2E Bilzen-Hoeselt | €60,825 | €13,548 | 86.9% | - |
| BRAMA CONSULT Asse | €67,486 | €13,305 | 12.0% | - |
These companies have the same main activity as FJ Pharma: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €60,800 and €76,600, founded between 2020 and 2022.
Official details
Source: KBO- Status
- Active since 20-07-2021Normal situation
- Activity
- Business and other management consultancyNACE 70200
- Establishment unit
- 2.320.838.9253730 Bilzen-Hoeselt, registered on 20-07-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 15-10-2025
Annual accounts 2025
- €66,403▲ 3.6%
- Filing
- Filed on 02-03-2026, 151 days before the end of the filing period
Insights on FJ Pharma
FJ Pharma files the micro format. That format states no turnover. The gross margin fell from €25,910 in 2022 to €13,684 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about FJ Pharma
- What is the company number of FJ Pharma?
- The company number of FJ Pharma is 0771.593.428. The VAT number is the same number with BE in front: BE 0771.593.428.
- Where is FJ Pharma based?
- The registered office is at Boeleberg 2, 3730 Bilzen-Hoeselt.Company details
- What does FJ Pharma do?
- According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
- What is the legal form of FJ Pharma?
- FJ Pharma is a private limited company (BV).
- When was FJ Pharma founded?
- FJ Pharma was founded on 20-07-2021.
- Is FJ Pharma still active?
- Yes, FJ Pharma is an active enterprise in the KBO register.
- What is the turnover of FJ Pharma?
- The turnover in financial year 2025 is ≈ €62,000. This figure is estimated from the gross margin of €13,684 and 256 comparable companies (NACE 70200). It probably lies between €28,000 and €120,000. It is a rough estimate.Financials
- Is FJ Pharma profitable?
- In financial year 2025, FJ Pharma made a profit of €8,035.
- Where can I find the annual accounts of FJ Pharma?
- FJ Pharma filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of FJ Pharma due?
- FJ Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.